drugset / Trial / NCT06433791
Evaluation of Ascorbate-Meglumine Therapeutic for SRS
Non-randomizedSequentialOpen-labelTreatment
Summary
Phase 1, Single-Center, Dose-Escalating, Open-Label, Safety Clinical Trial of Parenteral Ascorbate-Meglumine as a Novel Magnetic Resonance Imaging (MRI)-guided Adjunctive Therapeutic for Stereotactic Radiosurgery (SRS)
Timeline
- Start
- 2024-09-09
- Primary completion
- 2025-05-17
- Completion
- 2025-09-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Vitamin C | Other / unclassified | 9.6 g | Intravenous |
| Subject | Vitamin C | Other / unclassified | 18.6 g | Intravenous |
| Subject | Vitamin C | Other / unclassified | 37.8 g | Intravenous |
| Subject | Vitamin C | Other / unclassified | 75 g | Intravenous |
Indications
No indication recorded.